Imunon
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1982-01-01
- Employees
- 33
- Market Cap
- $16.7M
- Website
- http://imunon.com
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CarcinomaOvarian CancerFallopian Tube Cancer
- Interventions
- Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
- First Posted Date
- 2025-04-07
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Imunon
- Target Recruit Count
- 500
- Registration Number
- NCT06915025
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸Erlanger Health, Chattanooga, Tennessee, United States
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Imunon
- Target Recruit Count
- 24
- Registration Number
- NCT06283459
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸DM Clinical Research, Philadelphia, Pennsylvania, United States
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Imunon
- Target Recruit Count
- 50
- Registration Number
- NCT05739981
- Locations
- 🇺🇸
OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
- Conditions
- Primary Peritoneal CancerEpithelial Ovarian CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Imunon
- Target Recruit Count
- 130
- Registration Number
- NCT03393884
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Mitchell Cancer Institute (University of South Alabama), Mobile, Alabama, United States
🇺🇸Gynecologic Oncology Associates (Hoag Hospital), Newport Beach, California, United States
Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- Drug: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)Radiation: Radiation TherapyDevice: Superficial Hyperthermia
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Imunon
- Registration Number
- NCT02850419
- Locations
- 🇨🇿
Inst. of Radiation Oncology Hospital Na Bulovce, Prague, Czechia
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇹Fondazione Del Piemonte Per L'Oncologia - Irccs Candiolo, Candiolo, Italy
- Prev
- 1
- 2
- 3
- Next
News
IMUNON Secures Nasdaq Listing Extension to Advance Phase 3 Ovarian Cancer Immunotherapy
IMUNON received approval from the Nasdaq Hearing Panel for a listing extension after demonstrating compliance with equity requirements through recent fundraising activities.
Novel IL-12 Delivery System Shows Promise for Advanced Ovarian Cancer Treatment
Researchers are developing innovative non-viral delivery systems for IL-12 immunotherapy, targeting the tumor microenvironment while minimizing systemic toxicity in ovarian cancer treatment.
Imunon's DNA Plasmid Vaccine Shows Promising Safety and Immune Response in Clinical Trial
Imunon's novel DNA plasmid vaccine demonstrated a favorable safety profile with no serious adverse events reported in the clinical trial.
IMUNON's DNA Vaccine Shows Promising Immune Response Against COVID-19 in Phase 1 Trial
IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.
Imunon's IMNN-001 Shows Promise in Ovarian Cancer, Phase 3 Trial Planned
Imunon's IMNN-001, combined with chemotherapy, demonstrated an 11.1-month improvement in overall survival in patients with advanced ovarian cancer in the OVATION-2 trial.
IMUNON's IMNN-001 Shows Promise in Advanced Ovarian Cancer Treatment
IMUNON's IMNN-001, combined with standard chemotherapy, demonstrated a 35% improvement in overall survival for advanced ovarian cancer patients compared to chemotherapy alone.
IMUNON's IMNN-001 Shows Promise in Advanced Ovarian Cancer Treatment
• IMUNON's IMNN-001 demonstrated an 11.1-month overall survival improvement in advanced ovarian cancer patients compared to standard of care, marking a significant clinical advancement. • The OVATION 2 study highlighted a 35% survival improvement in the intent-to-treat population, with even greater benefits observed in patients also treated with PARP inhibitors. • IMUNON is preparing for an End-of-Phase 2 meeting with the FDA and plans to initiate a 500-patient pivotal Phase 3 study in early 2025. • New clinical data from the OVATION 2 Study of IMNN-001 was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
IMUNON's IMNN-001 Receives FDA Agreement on Manufacturing for Phase 3 Ovarian Cancer Trial
IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer.
IMUNON's IMNN-001 Demonstrates Significant Survival Benefit in Ovarian Cancer Phase 2 Trial
IMUNON's IMNN-001 Phase 2 OVATION 2 study showed an 11.1-month increase in median overall survival compared to standard care for ovarian cancer patients.
IMUNON's IMNN-001 Shows Promise in Advanced Ovarian Cancer Treatment
IMUNON will host an Ovarian Cancer R&D Day on September 18, 2024, featuring updates on IMNN-001, an investigational therapy for ovarian cancer.